- Home
- AACG vs RADX Comparison
AACG vs RADX Comparison
Compare AACG & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- RADX
- Stock Information
- Founded
- AACG 1999
- RADX 2021
- Country
- AACG China
- RADX Australia
- Employees
- AACG N/A
- RADX N/A
- Industry
- AACG Other Consumer Services
- RADX
- Sector
- AACG Real Estate
- RADX
- Exchange
- AACG Nasdaq
- RADX NYSE
- Market Cap
- AACG 28.2M
- RADX 32.5M
- IPO Year
- AACG N/A
- RADX N/A
- Fundamental
- Price
- AACG $0.77
- RADX $4.70
- Analyst Decision
- AACG
- RADX Strong Buy
- Analyst Count
- AACG 0
- RADX 2
- Target Price
- AACG N/A
- RADX $13.50
- AVG Volume (30 Days)
- AACG 11.4K
- RADX 21.1K
- Earning Date
- AACG 08-06-2025
- RADX 02-26-2025
- Dividend Yield
- AACG N/A
- RADX N/A
- EPS Growth
- AACG N/A
- RADX N/A
- EPS
- AACG N/A
- RADX N/A
- Revenue
- AACG $37,997,003.00
- RADX $204,609.00
- Revenue This Year
- AACG N/A
- RADX N/A
- Revenue Next Year
- AACG N/A
- RADX N/A
- P/E Ratio
- AACG N/A
- RADX N/A
- Revenue Growth
- AACG 21.24
- RADX N/A
- 52 Week Low
- AACG $0.50
- RADX $3.50
- 52 Week High
- AACG $1.10
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- AACG 35.81
- RADX N/A
- Support Level
- AACG $0.75
- RADX N/A
- Resistance Level
- AACG $0.86
- RADX N/A
- Average True Range (ATR)
- AACG 0.04
- RADX 0.00
- MACD
- AACG -0.01
- RADX 0.00
- Stochastic Oscillator
- AACG 11.71
- RADX 0.00
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments are Overseas art study services, Other educational services and K-12 education assessment and other services. Majority of its revenue comes from Overseas art study services.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.